Johnson & Johnson Aktie News

NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) will present at the Guggenheim Securities 2nd Annual Healthcare Innovation Conference on Tuesday, November 11th, 2025. Management will participate in a Fireside Chat at 10:30 a.m. Eastern Time. A live audio webcast of the presentation will be accessible through Johnson & Johnson's Investor Relations website at www.investor.jnj....

When investors hear that a company will lower prices on its products, their instinctive reaction is to expect a sequential decline in margins and profits, which is not entirely incorrect. However, sometimes these price decreases end up attracting new business, expanding market share, and more than making up for the lost ticket price in the top-line revenue.

While AI hype reigns on Wall Street, the healthcare sector is still far from the peaks it reached during the COVID-19 pandemic. And what's more important, many of the biotech stocks remain outside of Mr. Market's interest zone. Since the exclusivity of key blockbusters of 'giants', including Merck and Pfizer, expires in the next 4 years, there is an urgent need to continue rejuvenating their po...

Investors love dividend stocks, especially those with high yields, because they provide a substantial income stream and offer significant total return potential.

Verizon stands out as the only Dow stock meeting the 'dogcatcher' ideal: annual dividends from $1K invested exceed its share price. Analyst forecasts suggest top-ten Dow Dogs could deliver average net gains of 20% by October 2026, with VZ among the safer high-yield picks. Most Dow Dogs remain overpriced relative to their dividends, but market pullbacks could create fair-value opportunities for ...

Retirees and older individuals are among the biggest demographics who tune into Jim Cramer's Mad Money show.

The Dogs of the Dow is a well-known strategy first published in 1991 by Michael O'Higgins.

Over the past ten years, Johnson & Johnson (NYSE: JNJ) has delivered an impressive $157 Bil back to its investors through cash distributions via dividends and buybacks. This commitment to shareholder value has translated into exceptional market performance in 2025, with the stock delivering a remarkable 26% year-to-date return, significantly outpacing the broader healthcare sector and demonstra...